before COVID. before partnering with GSK. before running a successful COVID trial. before getting EUA for their drug.
In that they have a partnership with GSK, a successful COVID drug, EUA from the FDA and lots of funding. They're not just far ahead of us, they're in an entirely different league.
When we get: A big pharma partner. Run a successful COVID trial. Receive EUA from the FDA
Then we will probably be a multi-billion dollar company. My hope is that COVID results spark a buyout in the $2B range this fall.